Why Abbvie May Have A Tough Time Defending Humira's Price Before Congress

But when it comes to Humira, Abbvie sales have paid off the research and development costs multiple times over with plenty leftover for billions of dollars in profits. Humira, which treats autoimmune conditions including Crohn's disease and rheumatoid arthritis, can cost more than $50,000 a year , a review of company earnings reports shows.

Last year, Humira generated nearly $20 billion in sales for Abbvie in the drug's 16th year on the marketrevenue last year alone was almost triple what Abbvie’s former owner, Abbott Laboratories, paid to get HumiraNeither Abbvie nor its former parent company, Abbott, discovered Humira. Abbott under CEO Miles White came across Humira by acquisition, a 2001 purchase of Knoll PharmaceuticalsAbbott spun off its branded drug business in 2013 into what has become Abbvie.

When Abbott bought Humira, the biologic was already in the final stages of development and late stage clinical trials made the product look promising.including the popular thyroid treatment Synthroid and other brand name prescriptions that generated billions of dollars in sales over the years making the acquisition of Humira less of a financial risk.

About $24 billion in sales came from Humira from its first sale in 2003 through 2010. In 2011, Dr. Sidney Wolfe, who at the time headed Public Citizen’s health research group,“Humira has been a phenomenally successful product with application in a lot of different disease categories,"."Humira's got long legs, out until about at least 2016, when its first patents begin to expire.

But Humira’s legs have been getting even longer. Since the beginning of 2011, Humira has produced another $108 billion in sales through last year and Abbvie has a plan to keep the drug churning out billions more in sales and profits for years to come.

Source: News Formal (newsformal.com)

🥶 i don't know who else to tag to get this msg to Faiza Beauty CareemPAK

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Why Abbvie May Have A Tough Time Defending Humira's Price Before CongressDrug maker Abbvie may have to defend the price of its Humira treatment before the U.S. Senate Finance Committee today. The company was fighting in court to keep the biosimilar, Amjevita, approved by the FDA from being sold in the U.S. market. Just saw they settled at the end of January. Undisclosed. Interesting timing. A great example of a CEO who should be in prison
Source: Forbes - 🏆 394. / 53 Read more »

Voyager Therapeutics stock soars after AbbVie collaboration potentially valued at over $1 billion
Source: MarketWatch - 🏆 3. / 97 Read more »

World’s best-selling drug costs five times more in U.S. than EuropeCritics accuse the maker of Humira of exploiting U.S. patent laws to keep competitors’ less expensive versions off the market. The company, AbbVie, says it’s balancing the need to keep the drug affordable to patients with the need to fund new drug development. jwgop The oldest trick in big pharma’s book, sadly. No wonder people turn against capitalism when they see this kind of greed. The promise of capitalism and competition is to see lower prices. Clearly the US is getting ripped off here, and they allow it to happen. jwgop Check out the nuviguil/ proviguil scam. Literally paid generic manufacturers to not make it. Find a billion, then licensed it at insane levels for generics when they were introduced.
Source: NBCNews - 🏆 10. / 86 Read more »

Why Abbvie May Have A Tough Time Defending Humira's Price Before CongressDrug maker Abbvie may have to defend the price of its Humira treatment before the U.S. Senate Finance Committee today. The company was fighting in court to keep the biosimilar, Amjevita, approved by the FDA from being sold in the U.S. market. Just saw they settled at the end of January. Undisclosed. Interesting timing. A great example of a CEO who should be in prison
Source: Forbes - 🏆 394. / 53 Read more »

The US is having a tough time convincing the world's biggest democracy to ditch HuaweiAn Indian official told the Journal that Huawei 'can't be ignored' because it is at the forefront of 5G technology.
Source: BusinessInsider - 🏆 729. / 51 Read more »

The US is having a tough time persuading the world's biggest democracy to ditch HuaweiAn Indian official told The Wall Street Journal that Huawei 'can't be ignored' because it is at the forefront of 5G wireless technology. haniyeh_bagheri :))) یاد تو و نرگس افتادم :دی Folks, any comment on this? i recently changed to Huawei and it is amazing! I had to buy the phone abroad of course...
Source: BusinessInsider - 🏆 729. / 51 Read more »

Nigerian vote tough to call as week-long delay may hurt turnoutNigerian teacher Benjamin Shagu flew 500 km (310 miles) from the east of the cou... Let your sad as wait for it. BuhariMustGo Nigeria has a potential to become the biggest econonmy in Africa ; It has the largest population in the region + big oil production . But there is one huge cloud hanging in the air : diversity in Nigeria not always a good thing to the country if you know what I mean !
Source: Reuters - 🏆 2. / 97 Read more »

Catalyst defends $375,000 drug price after Bernie Sanders rebukeCatalyst Pharmaceuticals Inc, targeted by U.S. Senator Bernie Sanders for its hi... They get grants from the Govt, to dev and then charge us back Did any one else read this headline and think 'how tf do you defend that?' BernieSanders is a good person. Unfortunately there are not enough good people in the US to elect him to the presidency. Like the UK, the US is being lorded over by right wing thugs.
Source: Reuters - 🏆 2. / 97 Read more »

Catalyst Pharmaceuticals defends $375,000 drug price after Bernie Sanders rebukeCatalyst Pharmaceuticals Inc, rebuked by U.S. Senator Bernie Sanders for its hig... .. their 'defense' is that the 'other guys do it too' .. lol Murica Defending that earns a barf bag from me! They are going to force Medicare for all. That is what is going to happen.
Source: Reuters - 🏆 2. / 97 Read more »